MANAGEMENT TREATMENT OF PROLIFERATIVE LUPUS NEPHRITIS: A SYSTEMATIC REVIEW
Abstract
One common and dire manifestation that should be looked for in SLE is the involvement of the kidneys, known as lupus nephritis (LN). Proliferative lupus nephritis is the one of types lupus nephritis which is currently still a challenge in its management. prevent nephron damage, and CKD especially end-stage kidney disease (ESKD) by administering immunosuppressive agents to improve outcomes and prognosis. This qualitative study with a systematic review approach carried out an electronic search in Medline (PubMed interface), Google Scholar, Scopus, Elsevier and Web of Science, using the keyword. Literatures were extracted, duplicate screening, and pooled analysis finally included 10 studies in the qualitative study. The clinical trial literature in the last five years includes tacrolimus, azathioprine, rituximab, cyclosporine, belimumab, leflunomide, fish oil, obinutuzumab, and voclosporin which can be combined with standard therapy. Other literature also recommends abatacept, laquinimod, ocrelizumab, sirukumab, misoprostol, plasma exchange, IV immunoglobulin, and stem cell therapy which can be used for the proliferative therapy of lupus nephritis.
References
Parikh S V., Almaani S, Brodsky S, Rovin BH. Update on Lupus Nephritis: Core Curriculum 2020. American Journal of Kidney Diseases [Internet] Elsevier Inc; 2020;76(2):265–81. Available from: https://doi.org/ 10.1053/ j.ajkd.
10.017
Anders HJ, Saxena R, Zhao M hui, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nature Reviews Disease Primers [Internet] Springer US; 2020;6(1). Available from: http://dx.doi.org/10.1038/s41572-019-0141-9
George J. Management of lupus nephritis. Journal of Association of Physicians of India. 2003;51(MAY):489–94.
Wenderfer SE, Eldin KW. Lupus Nephritis. Pediatric Clinics of North America [Internet] Elsevier Inc; 2019;66(1):87–99. Available from: https://doi.org/10.1016/j.pcl.2018.08.007
Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupus nephritis: Clinical presentations and outcomes in the 21st century. Rheumatology (United Kingdom). 2020;59:V39–51.
Aggarwal A, Mehta S, Gupta D, Sheikh S, Pallagatti S, Singh R, et al. Clinical & immunological erythematosus patients characteristics in systemic lupus Maryam. Journal of dental education [Internet] 2012;76(11):1532–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23144490
Pinheiro SVB, Dias RF, Fabiano RCG, Araujo S de A, Silva ACSE. Pediatric lupus nephritis. Jornal brasileiro de nefrologia : ’orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia. 2019;41(2):252–65.
Musa; R, Brent; LH, Qurie. A. Lupus Nephritis. StatPearls [Internet] 2022; Available from: https://www.ncbi.nlm. nih.gov/books/NBK499817/
Mehra S, Usdadiya JB, Jain VK, Misra DP, Negi VS. Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study. Rheumatology International [Internet] Springer Berlin Heidelberg; 2018;38(4):557–68. Available from: http://dx.doi.org/10.1007/s00296-018-3995-3
Leyla Gadakchi, Hajialilo M, Mohammad-Reza, Nakhjavani, Azar SA, Kolahi S, et al. Efficacy and Safety of Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide as Induction Therapy in Proliferative Lupus Nephritis. Iranian Journal of Kidney Diseases. 2018;12(5).
Chowdhary P, Kale S, Sharma R. To study the efficacy and safety of tacrolimus and azathioprine combination as an induction therapy for proliferative lupus nephritis. Journal of The Nephrology Society. 2022;1(1):19.
Goswami RP, Sircar G, Sit H, Ghosh A, Ghosh P. Cyclophosphamide Versus Mycophenolate Versus Rituximab in Lupus Nephritis Remission Induction: A Historical Head-to-Head Comparative Study. Journal of Clinical Rheumatology. 2019;25(1):28–35.
Sheikholeslami M, Hajialilo M, Rasi Hashemi SS, Malek Mahdavi A, Gojazadeh M, Khabbazi A. Low dose cyclosporine A in the treatment of resistant proliferative lupus nephritis. Modern Rheumatology [Internet] Informa UK Limited, trading as Taylor & Francis Group; 2018;28(3):523–9. Available from: https://doi.org/10.1080/ 14397595.2017.1352479
Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. New England Journal of Medicine. 2020;383(12):1117–28.
Zhang M, Qi C, Zha Y, Chen J, Luo P, Wang L, et al. Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. Clinical Rheumatology. Clinical Rheumatology; 2019;38(3):859–67.
Zhang C, Ge C, Wang J, Sun D. Fish oil enhanced the efficacy of low-dose cyclophosphamide regimen for proliferative lupus nephritis: A randomized controlled double-blind trial. Food and Nutrition Research. 2021;65(June 2021):1–7.
Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Annals of the rheumatic diseases. 2022;81(1):100–7.
Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet [Internet] Elsevier Ltd; 2021;397(10289):2070–80. Available from: http://dx.doi.org/10.1016/ S0140-6736(21)00578-X
Meliambro K, Campbell KN, Chung M. Therapy for Proliferative Lupus Nephritis. Rheumatic Disease Clinics of North America [Internet] Elsevier Inc; 2018;44(4):545–60. Available from: https://doi.org/10.1016/j.rdc.2018.06. 002
Dall’Era M. Treatment of lupus nephritis: Current paradigms and emerging strategies. Current Opinion in Rheumatology. 2017;29(3):241–7.
Tunnicliffe DJ, Palmer SC. Immunosuppressive Treatment for Proliferative Lupus Nephritis: Summary of a Cochrane Review. American Journal of Kidney Diseases. 2018;72(5):756–7.
Hosoda T, Hashimoto S, Sato R, Fujita M, Aizawa T, Tsugawa K, et al. Abatacept as an alternative therapy for the treatment of drug-intolerant lupus nephritis: A case of underlying monosomy 1p36 deletion syndrome. Clinical Nephrology. 2022;97(5):309–10.
Cajamarca-Barón J, Buitrago-Bohórquez J, José Emmanuel Mendoza Orozco, Segura O, Guavita-Navarro D. Efficacy and safety of intravenous immunoglobulin in patients with lupus nephritis: A systematic review of the literature. Autoimmunity Reviews. 2022;21(11).
Liu B, Ou Q, Tang Y, Fu S, Liang P, Yu Y, et al. Corticosteroids combined with doublet or single-agent immunosuppressive therapy for active proliferative lupus nephritis. Clinical Rheumatology. Clinical Rheumatology; 2019;38(9):2519–28.
Fernández-Zarzoso M, Gómez-Seguí I, Rubia J de la. Therapeutic plasma exchange: Review of current indications. Transfusion and Apheresis Science. 2019;58(3):247–53.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
